Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of joining the study.
• People who have liver metastases (cancer that has spread to the liver from another part of the body) that cannot be removed by surgery.
• People whose cancer continued to grow or stopped responding to at least one previous treatment for their liver metastases.
• People who have previously received treatments that target blood vessel growth (antiangiogenic therapy) or a protein called EGFR are also considered eligible.
• People who have at least one area of disease that can be measured on a CT or MRI scan, based on standard criteria called RECIST.
• People whose general physical functioning falls within an acceptable range on a standard scale used by doctors (ECOG performance status of 2 or less).
• People with a life expectancy of at least 12 weeks.
• People whose blood counts, liver function, and kidney function meet specific minimum levels as determined by blood tests (confirm exact values with the trial site).
• Female patients who could become pregnant must have a negative pregnancy test taken within 7 days before starting the trial.
• People who are willing and able to follow all study requirements, including attending appointments, following contraception guidelines, and completing all scheduled assessments.

Who may not be able to join:

• People with a history of significant heart disease, or who have had a clinically serious gastrointestinal bleed within the 4 weeks before starting the study.
• People who have had a blood clot or stroke — including mini-strokes (transient ischemic attacks), deep vein thrombosis, or a clot in the lungs — within the 6 months before their first dose (with a limited exception for a specific type of portal vein clot — confirm with trial site).
• People who have previously been treated with a procedure called cryoablation (freezing tumours to destroy them).
• People who have had radiofrequency ablation (RFA) or surgical tumour removal less than 4 weeks before the planned study start date.
• People who have had radiotherapy less than 4 weeks before the planned study start date.
• People who have had major surgery within 4 weeks of starting the study, or who have not yet fully recovered from major surgery.
• People who have a second, separate cancer diagnosis, except for certain treated skin cancers or very early-stage cervical cell changes.
• People with a weakened immune system, including those who are known to be HIV-positive.
• People who have taken part in another clinical trial using an experimental treatment within the past 30 days before joining (or longer, depending on the previous trial drug — confirm with trial site).
• People with any of the following conditions, as these may affect the safety or results of the study:
  • A history of a lung condition called interstitial lung disease
  • Infection with both Hepatitis B and Hepatitis C at the same time
  • Known acute or long-term inflammation of the pancreas (pancreatitis)
  • Active tuberculosis
  • Any other active infection (viral, fungal, or bacterial) currently requiring treatment
  • A history of having received a donated organ or tissue transplant
  • A diagnosis of immune deficiency, or use of steroid or immune-suppressing medications within 7 days before the first dose
  • An active autoimmune disease (where the body's immune system attacks itself) requiring treatment within the past 3 months, or a history of severe autoimmune disease — though certain conditions such as vitiligo, stable thyroid conditions, type 1 diabetes, or mild asthma may be exceptions (confirm with trial site)
  • Receipt of a live vaccine within 30 days before the first dose of the study drug, or during the study
  • A history of cancer that has spread to the brain or spinal cord, unless treatment has been completed, the person has no symptoms, and steroids have not been needed for at least 6 weeks before starting the trial drug (confirm with trial site)
• People taking medications known to interfere with the drugs being used in the trial.
• People currently receiving any other active cancer treatment not specified in the study protocol.
• People who have taken any other experimental drug within 28 days of joining the study.
• People who are pregnant or breastfeeding, or people of reproductive potential who are not using an effective method of contraception (such as implants, injections, combined oral contraceptives, hormonal intrauterine devices, vasectomy of a partner, or complete sexual abstinence).
• People with a significant history of not following medical instructions, or who are unable to give reliable informed consent to participate.

Important: Always verify eligibility with the trial site directly before applying.